Subject-level prevalence for composite precision medicine opportunities, including actionable PGx, management of serious CYP-mediated DDIs, and management of DDIs including acid reducers and TKIs. CYP, cytochrome P450; DDI, drug-drug interaction; PGx, pharmacogenetics; TKI, tyrosine kinase inihibitors.